



4 Research Court, Suite 300
Rockville, MD 20850
877-411-2041
Services@ibtbioservices.com

Recombinant Vesicular Stomatitis Virus pseudotyped MARV-Angola glycoprotein

Catalog #: **1004-001**

Lot #: **2103002**

Description: Recombinant Vesicular Stomatitis Virus pseudotyped Angola marburgvirus glycoprotein (rVSV pseudotyped MARV-Angola GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV pseudotypes containing the envelope glycoprotein of Angola marburgvirus. Since the infectivity of rVSV pseudotyped MARV-Angola GP is restricted to a single round of replication, analyses of viral entry can be performed using just biosafety level 2 (BSL-2) containment. Infectivity and neutralization of infectivity can be measured by luciferase activity.

Storage: -80°C

Size: 25 µL @ 4.02e8 RLU*/mL is supplied in Advanced DMEM supplemented with 1% Fetal Bovine Serum, L-glutamine and Penicillin/Streptomycin, sufficient for one 96-well assay.

***RLU = Relative Light Units**

Relevance: This rVSV contains MARV-Angola glycoprotein and serves as a tool to enhance filovirus research performed using just biosafety level 2 (BSL-2) containment.


Related Products: IBT provides a wide array of anti-filovirus specific antibodies and other infectious disease reagents. Please see our website, www.ibtbioservices.com for more details.

Intended for research use only, not for human, therapeutic, or diagnostic applications.

The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, Inc.

Copyright 2021. Integrated BioTherapeutics, Inc. All rights reserved.

Neutralization Data:



An anti-MARV mAb starting at 4 µg/mL, followed by four-fold serial dilutions, was incubated with the rVSV pseudotyped with MARV-Angola GP, for one hour prior to adding to Vero cells. Infectivity was determined the next day by assessing luciferase activity. Percent neutralization was calculated based on the controls.

$[1 - (\text{RLU of treated well} - \text{RLU of Cells only}) / (\text{RLU of Virus only} - \text{RLU of Cells only})] * 100$

References:

1. Whitt, M.A., Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods, 2010. 169(2): p. 365-74.